03/2012 journal articles
CLINICAL AND BIOLOGICAL MARKERS OF SARCOPENIA: WHERE ARE WE?
S. Studenski
J Frailty Aging 2012;1(3):95-96
Show summaryHide summary
CITATION:
S. Studenski (2012): Clinical and biological markers of sarcopenia: where are we?. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.14
IMAGING, FUNCTIONAL AND BIOLOGICAL MARKERS FOR SARCOPENIA: THE PURSUIT OF THE GOLDEN RATIO
E. Marzetti
J Frailty Aging 2012;1(3):97-98
Show summaryHide summary
CITATION:
E. Marzetti ; (2012): Imaging, functional and biological markers for sarcopenia: the pursuit of the golden ratio. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.15
SARCOPENIA: HAVE WE REACHED THE CONSENSUS?
L.-K. Chen
J Frailty Aging 2012;1(3):99-101
Show summaryHide summary
CITATION:
L.-K. Chen (2012): Sarcopenia: Have We Reached the Consensus?. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.16
BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS RECOMMENDATIONS FROM THE INTERNATIONAL WORKING GROUP ON SARCOPENIA
M. Cesari, R.A. Fielding, M. Pahor, B. Goodpaster, M. Hellerstein, G. Abellan Van Kan, S.D. Anker, S. Rutkove, J.W. Vrijbloed, M. Isaac, Y. Rolland, C. M’Rini, M. Aubertin-Leheudre, J.M. Cedarbaum, M. Zamboni, C.C. Sieber, D. Laurent, W.J. Evans, R. Roubenoff, J.E. Morley, B.Vellas, for the International Working Group on Sarcopenia
J Frailty Aging 2012;1(3):102-110
Show summaryHide summarySarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and socioeconomic negative outcomes in older persons. The study of this phenomenon and the development of preventive/therapeutic strategies represent public health priorities. The present document reports the results of a recent meeting of the International Working Group on Sarcopenia (a task force consisting of geriatricians and scientists from academia and industry) held on June 7-8, 2011 in Toulouse (France). The meeting was specifically focused at gaining knowledge on the currently available biomarkers (functional, biological, or imaging-related) that could be utilized in clinical trials of sarcopenia and considered the most reliable and promising to evaluate age-related modifications of skeletal muscle. Specific recommendations about the assessment of aging skeletal muscle in older people and the optimal methodological design of studies on sarcopenia were also discussed and finalized. Although the study of skeletal muscle decline is still in a very preliminary phase, the potential great benefits derived from a better understanding and treatment of this condition should encourage research on sarcopenia. However, the reasonable uncertainties (derived from exploring a novel field and the exponential acceleration of scientific progress) require the adoption of a cautious and comprehensive approach to the subject.
CITATION:
M. Cesari ; R.A. Fielding ; M. Pahor ; B. Goodpaster ; M. Hellerstein ; G. Abellan Van Kan ; S.D. Anker ; S. Rutkove ; J.W. Vrijbloed ; M. Isaac ; Y. Rolland ; C. M’Rini ; M. Aubertin-Leheudre ; J.M. Cedarbaum ; M. Zamboni ; C.C. Sieber ; D. Laurent ; W.J. Evans ; R. Roubenoff ; J.E. Morley ; B.Vellas ; for the International Working Group on Sarcopenia (2012): Biomarkers of sarcopenia in clinical trials Recommendations from the International Working Group on Sarcopenia. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.17
THE PHENOTYPE OF FRAILTY PREDICTS DISABILITY AND MORTALITY AMONG MEXICAN COMMUNITY-DWELLING ELDERLY
S. Aguilar-Navarro, L.M. Gutiérrez-Robledo, J.M.A. García-Lara, H. Payette, H. Amieva, J.A. Avila-Funes
J Frailty Aging 2012;1(3):111-117
Show summaryHide summaryBackground: Frailty represents a major public health priority in Western countries. Specific social and cultural factors may influence the prevalence and predictive value for negative health-related events of this syndrome. Objective: To determine the prevalence and predictive value of the phenotype of frailty among community-dwelling Mexican American older persons. Design, Setting and Participants: Two-year longitudinal study of 5,644 men and women aged 60 years and older participating in the Mexican Health and Aging Study. Measurements: The Frailty index used in the present study was a modified version of the operational definition proposed in the Cardiovascular Health Study (CHS). Frailty was defined by the presence of at least three of the four following criteria: weight loss, weakness, exhaustion, slowness, and low physical activity. The main outcomes were incident disability and mortality. Chi-square, ANOVA and multiple logistic regression analyses were used to test the prognostic value of frailty for the outcomes of interest. Results: The mean age of the study sample was 68.7 (SD 6.9) years. Thirty-seven percent of participants (n=2,102) met the definition of frailty. Frail subjects were significantly older, and more likely to be women than non-frail participants. They also presented lower education, more chronic diseases, lower income, and poorer self-reported health status. After adjusting for potential confounders, frailty was found to be a predictor of incident mobility disability (odds ratio [OR] 1.91, 95% confidence interval [CI] 1.37-2.66), activities of daily living (ADL) disability (OR 9.33; 95%CI 3.37-25.82), and instrumental ADL (IADL) disability (OR 1.81, 95%CI 1.23-2.68). The risk of mortality among frail participants was almost three-fold higher than in non-frail ones. Conclusion: The prevalence of frailty is higher in this elderly population than what previously reported in other cohorts. The phenotype of frailty was confirmed to be a predictor for adverse health-related outcomes (including mobility, ADL, and IADL disability). Further studies in Latin American countries are needed to identify frailty and develop adapted interventions for the prevention of adverse outcomes in older persons.
CITATION:
S. Aguilar-Navarro ; L.M. Gutiérrez-Robledo ; J.M.A. García-Lara ; H. Payette ; H. Amieva ; J.A. Avila-Funes (2012): THE PHENOTYPE OF FRAILTY PREDICTS DISABILITY AND MORTALITY AMONG MEXICAN COMMUNITY-DWELLING ELDERLY. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.18
PREDICTIVE DEMI-SPAN EQUATIONS FOR ESTIMATION OF STATURE IN AGED MEXICAN AMERICANS
C. Siordia, L.J. Panas, K.Markides
J Frailty Aging 2012;1(3):118-122
Show summaryHide summaryObjectives: To develop demi-span height predictive equations for older Mexican Americans. Design: Cross-sectional study. Setting: Data files housed by the Sociomedical Division in the department of Community Health and Preventive Medicine at the University of Texas Medical Branch in Galveston, Texas. Participants: 1,078 (700 females, 378 males) Southwest U.S.A. community-dwelling older Mexican Americans, aged 80-102 years. Measurements: Demi-span, height, weight, BMI, demi-span equivalent height (DSEH), DSEH derived BMI (DS-BMI). Bland and Altman agreement analysis on: height and DSEH; BMI and DS-BMI. Paired t-test comparing derived and actual measures by single-age units and sex. Results: DSEH with Bassey equations (DSEHBassey) are significantly different than actual measures. DSEHBassey derived BMIs (DSBasseyBMIs) are significantly different than BMIs computed from actual measures. DSEH with Mexican equations (DSEHMexican) are not significantly different than real measures. DSEHMexican derived BMIs (DSMexicanBMIs) are not significantly different than real measures. Conclusions: These findings provide evidence that both DSEHBassey and DSBasseyBMIs estimates are significantly different from measured height and BMI. Both DSEHMexican and DSMexicanBMIs estimates are shown to produce similar height and BMI estimates to those obtained from real measures.
CITATION:
C. Siordia ; L.J. Panas ; K. Markides (2012): Predictive Demi-Span Equations for Estimation of Stature in Aged Mexican Americans. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.19
CONCURRENCE OF FRAILTY AND PARKINSON’S DISEASE
K.P. Roland, K.M.D. Cornett, O. Theou, J.M. Jakobi, G.R. Jones
J Frailty Aging 2012;1(3):123-127
Show summaryHide summaryBackground: Females with Parkinson’s disease (PD) are at greater risk of frailty than males. Little is known about how age and disease-related characteristics influence frailty in females with PD because frailty studies often exclude persons with underlying neurological pathologies. Objective: To determine age and disease-related characteristics that best explain physical frailty in community-dwelling females with and without PD. Design & Measurement: Correlation coefficients described relationships between PD-related characteristics and physical frailty phenotype criteria (Cardiovascular Health Study). Regression analysis identified associations between disease-related characteristics and frailty in non-PD and PD females. Setting: Community-dwelling. Participants: Females with mild to moderate PD (n = 17, mean age = 66 ± 8.5 years) and non-PD (n = 18, mean age = 72 ± 13.2 years) participated. Results: Daily carbidopa-levodopa dose best explained frailty in PD females (β = 0.5), whereas in non-PD females, age (β = 0.7) and comorbidity (β = 0.5) were most associated with frailty. Conclusions: Dopaminergic medication explained frailty in PD and not measures of disease progression (i.e. severity, duration). In females without PD age-related accumulation of comorbidities resulted in greater risk of frailty. This indicates dopaminergic management of PD symptoms may better reflect frailty in females with PD than disease severity or duration. These data suggest the influence of underlying frailty should be considered when managing neurological conditions. Understanding how frailty concurrently exists with PD and how these conditions progress within the aging female will facilitate future care management.
CITATION:
K.P. Roland ; K.M.D. Cornett ; O. Theou ; J.M. Jakobi ; G.R. Jones (2012): Concurrence of Frailty and Parkinson’s disease. The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.20
CANCER-RELATED ANEMIA AND FRAILTY IN OLDER PERSONS
F. Cerullo, G. Gambassi, M. Cesari
J Frailty Aging 2012;1(3):128-136
Show summaryHide summaryAnemia, defined by the World Health Organization as a hemoglobin concentration lower than 13 g/dL in men and 12 g/dL in women, is particularly prevalent at advanced age. Nevertheless, it is not a condition simply explained by the normal aging process. Anemia represents a potentially reversible condition associated with numerous adverse health-related events, including hospitalization, disability, and mortality in older persons. Low haemoglobin concentrations are particularly common among patients with cancer due to direct (e.g., micro- and macroscopic blood losses) and indirect causes (e.g., increased production of pro-inflammatory cytokines with consequent reduction of erythropoietin release and erythropoiesis). The impaired oxygen-carrying capacity caused by the presence of anemia may play a major role in multiple clinical manifestations of cancer, such as dyspnea, fatigue, exhaustion, dizziness and/or headache. In the present review, we discuss the importance of low hemoglobin concentrations and anemia as important determinants of the frailty syndrome, a condition commonly present among cancer patients. Treatment of cancer-related anemia may improve quality of life and health-related outcomes (including disability and mortality) in older patients with oncological conditions.
CITATION:
F. Cerullo ; G. Gambassi ; M. Cesari (2012): Cancer-related anemia and frailty in older persons . The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.21
DESIGN OF A PHYSICAL ACTIVITY PROGRAM TO PREVENT FUNCTIONAL DECLINE IN ONCO-GERIATRIC PATIENTS (CAPADOGE): A RANDOMIZED MULTICENTER TRIAL
J. Durrieu, A. Doussau, A. Rieger, E. Terrebonne, K. Bouabdallah, M-D. Zwolakowski, B. Maget, J. Dauba, C. Mariette, S. Trager, J-L. Périé, B. Robert, S.C. Regueme, I. Bourdel-Marchasson
J Frailty Aging 2012;1(3):138-143
Show summaryHide summaryBackground: Cancer in older patient favours the development of frailty: feeling of exhaustion, loss of weight, decreased muscle strength, slow gait speed, and low physical activity. Objectives: To evaluate the efficacy of adapted physical activity phone advices in limiting the cancer-induced loss of autonomy and frailty phenotype development. Design: Multicenter randomized controlled trial. Setting: Patients (>70y) undergoing curative treatment for cancer (n=400) will be recruited from 12 centres. Intervention: The intervention consists in phoned personalized physical activity advices related to strength, aerobic, balance, proprioception, and flexibility. The contacts are performed twice a month during six months and then monthly until 1 year. The intervention complements the PNNS booklet advices (National Nutritional Health Program). The trial compares "individualized phone advices + PNNS" to "usual care + PNNS". Measurements: Functional, cognitive, clinical and self-reported data are assessed before treatment and at 3, 6, 12, 18, and 24 month follow-up. The primary outcome is the proportion of subjects with a one-year decreased SPPB (Short Physical Performance Battery) score of one point or more, as compared to baseline. The secondary outcomes include quality of life items, rate of hospitalizations, institutionalizations, mortality, Fried phenotype at 1 and 2 years, and the SPPB score at 2 years. Discussion: This large trial will provide clinical data of the effects of an exercise advices intervention in older patients during cancer therapy on function and cognition evolution, and quality of life. The possibilities of minimizing the development of frailty phenotype due to these advices will be explored.
CITATION:
J. Durrieu ; A. Doussau ; A. Rieger ; E. Terrebonne ; K. Bouabdallah ; M.-D. Zwolakowski ; B. Maget ; J. Dauba ; C. Mariette ; S. Trager ; J.-L. Périé ; B. Robert ; S.C. Regueme ; I. Bourdel-Marchasson (2012): DESIGN OF A PHYSICAL ACTIVITY PROGRAM TO PREVENT FUNCTIONAL DECLINE IN ONCO-GERIATRIC PATIENTS (CAPADOGE): A RANDOMIZED MULTICENTER TRIAL . The Journal of Frailty and Aging (JFA). http://dx.doi.org/10.14283/jfa.2012.22